ARGENICA THERAPEUTICS LIMITED

1.89%

26.0¢

Market Cap $33.39M

Healthcare Biotechnology

Argenica Therapeutics Limited is an Australia-based biotechnology company, developing... Argenica Therapeutics Limited is an Australia-based biotechnology company, developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. The Company's lead neuroprotective peptide candidate, ARG-007, has been demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischemic encephalopathy (HIE). The Company has completed a Phase I clinical trial in healthy human volunteers to assess the safety and tolerability of a single dose of ARG-007. It has completed dosing in a Phase II clinical trial in ischaemic stroke patients and continues to generate preclinical data in other neurological conditions, including in TBI and HIE.More

Latest Threads

Tag

Subject

AGN

Ann: Successful Applicaton for EMA Paediatric Waiver

07/02/26

998

07/02/26

Last post TorresdelPaine1

998

AGN

Ann: Investor Presentation - Euroz Hartleys Healthcare Conference

05/02/26

364

05/02/26

Last post smokeandfire

364

AGN

Ann: Quarterly Activities/Appendix 4C Cash Flow Report

28/01/26

458

28/01/26

Last post Odds&Evens

458

AGN Biotech

AGN share price/chart

23/01/26

5.6K

23/01/26

Last post Punditman

5.6K

AGN

Ann: Final Director's Interest Notice

02/01/26

279

02/01/26

Last post

ASX News

279

AGN

Ann: Non-Executive Chair Resignation

29/12/25

390

29/12/25

Last post

ASX News

390

AGN

AGN Media thread

8 9 10

12/12/25

558

171K

12/12/25

Last post Scottsmyname

558

171K

AGN

Ann: AI Analysis Reveals Efficacy In Severe Stroke Patients

11/12/25

2.6K

11/12/25

Last post Scottsmyname

2.6K

See All Discussions

Timeline

Investor Presentation - Euroz Hartleys Healthcare Conference
05 Feb 08:23	Share

Successful Applicaton for EMA Paediatric Waiver
02 Feb 09:01	Share

Quarterly Activities/Appendix 4C Cash Flow Report
28 Jan 08:15	Share

Final Director's Interest Notice
02 Jan 16:53	Share

Non-Executive Chair Resignation
29 Dec 08:27	Share

AI Analysis Reveals Efficacy In Severe Stroke Patients
11 Dec 09:11	Share

Positive TNK Study Results Fulfil Key FDA Requirement
04 Dec 08:17	Share

ARG-007 Efficacious Dose Validated in New Preclinical Study
25 Nov 09:16	Share

Final Director's Interest Notice
12 Nov 19:05	Share

Results of Annual General Meeting
12 Nov 19:03	Share

AGM Chair's Address & Presentation
12 Nov 16:53	Share

Non-Executive Director Retirement
12 Nov 16:49	Share

Quarterly Activities/Appendix 4C Cash Flow Report
31 Oct 09:16	Share

Investor Presentation - Cannacord Dug & Device Conference
21 Oct 09:04	Share

Notification regarding unquoted securities - AGN
20 Oct 13:16	Share

Phase 2 Trial Promising Improvements in Functional Outcomes
15 Oct 08:28	Share

Notice of Annual General Meeting/Proxy Form
13 Oct 14:09	Share

ASX Small Caps Conference Presentation
24 Sep 10:49	Share

Date of AGM & Closing Date for Director Nominations
17 Sep 08:57	Share

Change in substantial holding
04 Sep 08:17	Share

Investor Webinar
03 Sep 09:37	Share

Investor Presentation
03 Sep 09:35	Share

Topline Phase 2 Trial Results of ARG-007 in AIS Patients
03 Sep 09:34	Share

Trading Halt
01 Sep 09:01	Share

Appendix 4G & Corporate Governance Statement
28 Aug 17:06	Share

Appendix 4E & Annual Report to 30 June 2025
28 Aug 17:05	Share

Argenica Receives IND Feedback From FDA
14 Aug 09:08	Share

Bioshares Biotech Summit Presentation
08 Aug 09:11	Share

Argenica Appoints Vice President of Regulatory Affairs
06 Aug 08:15	Share

Ceasing to be a substantial holder from IFL
23 Jul 15:48	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 26.0¢		Change -0.005(1.89%)		Mkt cap ! $33.39M

Open	High	Low	Volume
26.5¢	26.5¢	26.0¢	97.11K

Buyers (Bids)

Vol.	Price($)
40964	26.0¢

Sellers (Offers)

Price($)	Vol.
27.0¢	13731

Last trade - 12.00pm 09/02/2026 (20 minute delay)

AGN (ASX) Chart

ARGENICA THERAPEUTICS LIMITED

Latest Threads

LM1 Strikes High-Grade Gold at Evanston, Growth Potential Builds

Timeline

Featured News

Latest Videos

Argenica Therapeutics (ASX:AGN) receives $350k cash boost to advance Alzheimers Studies

22 Feb 2023 12:03 (AEDT)

Argenica Therapeutics (ASX:AGN) pre-clinical data points to potential new Alzheimer's treatment

09 Feb 2023 12:02 (AEDT)

Argenica Therapeutic (ASX:AGN) receives $1.2m grant for traumatic brain injury project

20 Jan 2023 11:39 (AEDT)

Latest Articles

Argenica doses final patients in acute ischaemic stroke trial

Argenica Therapeutics Ltd has taken an important step in completion of its Phase 2 trial to test the efficacy and safety of ARG-007

Argenica rat brain study shows potential neuroprotective action in ARG-007

Argenica Therapeutics's rat study of its traumatic brain injury drug ARG-007 has shown early-stage evidence of neuroprotective action.

FDA awards Argenica two key designations for drug candidate targeting infant brain injury

Argenica Therapeutics Ltd has received two key designations from the US Food and Drug Administration for its ARG-006 candidate

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News